| |
Article Title |
Author(s) |
Pages |
|
|
|
Editorial Board
|
|
ii
|
|
|
|
Acknowledgements*
|
|
v
|
|
|
|
EORTC – NCI – ASCO Annual Meeting on “Molecular Markers in Cancer”
|
Jean-Yves Blay,
Nadia Harbeck
|
ix
|
|
|
|
Faculty list
|
Jean-Yves Blay,
Nadia Harbeck
|
x-xi
|
|
|
|
Societies' profiles
|
|
xiii-xv
|
|
|
|
SCIENTIFIC PROGRAM – OVERVIEW
|
|
xvi
|
|
|
|
Scientific Program – Details
|
|
xvii-xx
|
|
|
|
Faculty's Biosketches
|
|
xxi-xxxvi
|
|
|
|
SP 116 Omics-based tests: What is the evidence and how to present it?
|
J. Bogaerts
|
S1
|
|
|
|
SP 119 synthetic lethal approaches and biomarker discovery related to radiation sensitization in prostate cancer
|
R. Bristow
|
S1
|
|
|
|
SP 127 Adapting treatment in metastatic and adjuvant phases to the nature of mutation: the example of GIST
|
M. Debiec-Rychter
|
S1
|
|
|
|
SP 128 KRAS mutations in colorectal cancer: lessons learned and future progress
|
S.G. Eckhardt
|
S1-S2
|
|
|
|
SP 122 Debate on access to tissue specimens from clinical trials: when is the preliminary data strong enough to invest in highly annotated biospecimens?
|
J. Hall
|
S2
|
|
|
|
SP 132 IDH1/IDH2 mutations predict survival in glioma and AML
|
M. Hegi
|
S2
|
|
|
|
SP 134 Predictive and pharmacodynamic markers of susceptibility for targeting IGF-1R receptor
|
F.R. Hirsch
|
S2
|
|
|
|
SP 113 Translating molecular imaging agents into phase 3 trials
|
P. Jacobs
|
S2-S3
|
|
|
|
SP 108 Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia
|
T. Lion
|
S3
|
|
|
|
SP 131 MicroRNAs as prognostic and predictive markers in breast cancer
|
J. Martens
|
S3
|
|
|
|
SP 115 Cancer stem cells
|
W. Matsui
|
S3
|
|
|
|
SP 117 Using genomic landscapes to map biomarkers of drug sensitivity
|
U. McDermott
|
S3
|
|
|
|
SP 121 Requirements for prospective use of omics-based tests in NCI-sponsored trials
|
L.M. McShane
|
S4
|
|
|
|
SP 126 FLT3 is a stratification factor for targeted therapy treatments in adult and pediatric AML phase III trials
|
S. Meshinchi
|
S4
|
|
|
|
SP 135 Biomarkers for targeted therapy selection in non-small cell lung cancer (NSCLC)
|
L. Paz-Ares
|
S4
|
|
|
|
SP 130 Driving discovery through data integration and analysis
|
J. Quackenbush
|
S4
|
|
|
|
SP 129 International Cancer Genome Consortium: a promising story in pancreatic cancer
|
A. Scarpa
|
S4
|
|
|
|
SP 125 Functional activity versus clinical predictivity
|
L. Shankar
|
S5
|
|
|
|
SP 110 Epigenetics and drug resistance
|
S. Sharma
|
S5
|
|
|
|
SP 123 Overcoming drug resistance in melanoma
|
J.A. Sosman
|
S5
|
|
|
|
SP 111 miRNA and lung cancer: early detection in high-risk subjects
|
G. Sozzi
|
S5
|
|
|
|
SP 133 TCGA - success story in ovarian cancer
|
P. Spellman
|
S6
|
|
|
|
SP 114 Predictive and pharmacodynamic (PD) markers of PI3K pathway inhibitors: focus on PI3K, AKT and mTOR inhibitors
|
J. Tabernero
|
S6
|
|
|
|
SP 118 MDM2 inhibitors to reactivate p53 in human cancer
|
L. Vassilev
|
S6
|
|
|
|
SP 120 Various molecular forms of ALK predict sensitivity to targeted therapy in hematological and solid tumors
|
M.A. Wasik
|
S6
|
|
|
|
SP 112 Integration of metabolic imaging (PET CT) into clinical trials
|
W. Weber
|
S6-S7
|
|
|
|
SP 109 Meta-analysis of genomic datasets for robust signature discovery and disease characterization
|
L. Wessels
|
S7
|
|
|
|
SP 124 Debate on strategies for data release: controlled access
|
D.L. Wickerham
|
S7
|
|
|
|
OP 54 A genomic-based signature of response to chemotherapy in ovarian cancer fails to predict clinical outcome in two independent cohorts.
|
W. Barry,
W. Chen,
G. Sfakianos,
P. Isner,
M. Datto,
N. Kuderer,
G. Lyman,
A. Abernethy,
G. Ginsburg,
A. Berchuck
et al.
|
S8
|
|
|
|
OP 50 Initial experience with the EANM accreditation procedure of FDG PET/CT devices
|
R. Boellaard,
I. Hristova,
S. Ettinger,
S. Stroobants,
A. Chiti,
A. Bauer,
K. Tatsch,
P. Bourguet,
J. Bean,
W. Oyen
et al.
|
S8
|
|
|
|
OP 93 The co-development of a folate receptor molecular diagnostic imaging agent (99mTc-EC20) and folate receptor targeted drug conjugate (EC145) in the treatment of ovarian cancer patients
|
S. Ghamande,
L. Gilbert,
R. Penson,
E. Palmer,
J. Scott,
J. Symanowski,
R. Messmann,
B. Nguyen
et al.
|
S8
|
|
|
|
OP 29 Development of a genomic-clinical classifier model for predicting clinical recurrence in patients with localized prostate cancer
|
R. Jenkins,
A. Crisan,
N. Erho,
K.V. Ballman,
E.J. Bergstralh,
S.R. Fink,
T.M. Kollmeyer,
C. Buerki,
P.C. Black,
E. Davicioni
et al.
|
S8-S9
|
|
|
|
OP 16 Identification of JAK2/STAT3 as a novel therapeutic target in Kras mutant colorectal cancer models
|
M. Kalimutho,
R. Carson,
P. Dunne,
D. Longley,
P. Johnston,
S. Van Schaeybroeck
et al.
|
S9
|
|
|
|
OP 24 Somatic allelic selection in the tumor as an indicator of cancer relevance: insights from statistical mining of the Cancer Genome Atlas data
|
T. LaFramboise,
M. Freedman,
I. Pe'er,
K. Wilkins,
G. Yavas,
N. Dewal
et al.
|
S9
|
|
|
|
OP 75 An unbiased shRNA based lentiviral screen identifies tyrosine kinases that are important for survival and radioresistance in Head and Neck Squamous Cell Carcinoma
|
E-J. Van Limbergen,
P. Zabrocki,
M. Porcu,
E. Hauben,
J. Cools,
S. Nuyts
et al.
|
S9-S10
|
|
|
|
OP 85 Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab
|
K. Yonesaka,
K. Zejnullahu,
I. Okamoto,
T. Satoh,
F. Cappuzzo,
J. Souglakos,
J. Engelman,
M. Varella-Garcia,
K. Nakagawa,
P. Jänne
et al.
|
S10
|
|
|
|
PP 65 Are GSK2118436 and GSK1120212 effective in melanoma cell lines harboring V600BRAF mutations different from the common V600EBRAF variant?
|
P.A. Ascierto,
G. Gentilcore,
G. Madonna,
E. Assunta,
G. Pirozzi,
E. De Maio,
M. Curvietto,
G. Palmieri,
N. Mozzillo,
J. Legos
et al.
|
S11
|
|
|
|
PP 99 Effect of temozolomide on the U-118 glioma cell line
|
J. Balça-Silva,
A. Carmo,
M.C. Lopes
|
S11
|
|
|
|
PP 7 The non-small cell lung cancers exhibit distinct response phenotypes to telomerase inhibitor imetelstat
|
E. Bassett,
R. Frink,
A. Augustyn,
L. Girard,
N. Go,
J. Schiller,
W. Wright,
J. Shay,
J. Minn
et al.
|
S11
|
|
|
|
PP 36 Highly-specific and sensitive hydrolysis probe-based real-time PCR detection of epidermal growth factor receptor variant III in oral squamous cell carcinoma
|
P. Bose,
J.B. McIntyre,
A.C. Klimowicz,
N.T. Brockton,
S. Petrilllo,
W. Matthews,
J. Easaw,
A. Magliocco,
J.C. Dort
et al.
|
S11-S12
|
|
|
|
PP 15 BRCA1 expression is required for efficacy of vinorelbine and is a predictive biomarker in malignant mesothelioma
|
S. Busacca,
M. Sheaff,
S.G. Gray,
K.J. O'Byrne,
K. Kerr,
I. Schmitt-Opitz,
A. Soltermann,
H. Pass,
J.E. Quinn,
D.A. Fennell
et al.
|
S12
|
|
|
|
PP 44 Myeloid zinc finger 1 regulates thymidylate synthase expression in patients with metastatic colorectal cancer showing the same promoter gene polymorphism
|
A. Calascibetta,
F. Contino,
S. Feo,
A. Martorana,
R. Sanguedolce
et al.
|
S12
|
|
|
|
PP 77 Dissecting time- from tumor-related gene expression variability in the bilateral breast cancer model
|
M. Callari,
M. Dugo,
V. Cappelletti,
V. Musella,
R. Agresti,
M.G. Daidone
et al.
|
S12
|
|
|
|
PP 83 Gene expression profiling of circulating tumor cells in breast cancer
|
V. Cappelletti,
E. Fina,
P. Miodini,
M. Callari,
V. Musella,
R. Agresti,
A. Moliterni,
M.G. Daidone
et al.
|
S12-S13
|
|
|
|
PP 13 Urine cell free DNA integrity as a marker for early diagnosis of non invasive bladder cancer
|
V. Casadio,
C. Molinari,
R. Gunelli,
R. Silvestrini,
M. Tebaldi,
D. Amadori,
D. Calistri
et al.
|
S13
|
|
|
|
PP 81 Alternative splicing studies for the identification of novel cancer markers
|
A-S. Casagrande,
V. Kotraiah,
D. Toema,
D. Kong,
F. Mahé,
M. Pando,
L. Desire
et al.
|
S13
|
|
|
|
PP 14 mTOR inhibition decreases the malignant properties of cancer cells at selective stages of breast cancer progression in vitro
|
O. Cherednyk,
A. Khoruzhenko,
V. Kukharchuk,
V. Filonenko
|
S13
|
|
|
|
PP 33 Detection of prostate cancer by plasma proteome profiling based on matrix-assisted laser desorption/ionization time-of-flight mass spectrometry
|
V. Chernyaev,
V.E. Shevchenko,
N.E. Arnotskaya,
V.A. Chernyaev,
V.B. Matveev
et al.
|
S13-S14
|
|
|
|
PP 18 Transglutaminase 2 as an independent prognostic marker for the survival of Korean patients with non-small cell lung cancer
|
C-M. Choi,
S-J. Jang,
B-H. Nam,
H-R. Kim,
S-Y. Kim,
K-M. Hong
et al.
|
S14
|
|
|
|
PP 35 Evaluation of betaV-tubulin expression as novel predictive biomarker for clinical benefit from treatment with taxanes in non-small cell lung cancer (NSCLC)
|
D. Christoph,
T. Gauler,
M. Engelhard,
D. Theegarten,
C. Poettgen,
R. Hepp,
M. Schuler,
F. Hirsch,
W. Eberhardt,
J. Wohlschlaeger
et al.
|
S14
|
|
|
|
PP 100 Detection of DNA methylation biomarkers in sputum samples for the confirmation of NSCLC
|
J. Clark,
M. Kelly,
F. Moreau,
J. Bigley,
D. Iden,
S. Belinsky
et al.
|
S14
|
|
|
|
PP 4 Identification of specific biomarkers for glioma-initiating cells and glioma tumors
|
V. Clément-Schatlo,
M. Tenan,
B. Schatlo,
D. Marino,
K. Burkhardt,
K. Schaller,
I. Radovanovic
et al.
|
S14-S15
|
|
